Compare Stocks: NTN, CNTX, EVAX, and MCRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.26 -7.1%	$0.39	$0.25 ▼ $3.62	$25.27M	1.71	1.01 million shs	955,139 shs
EVAX Evaxion A/S	$2.80 +1.4%	$3.15	$2.72 ▼ $12.15	$24.90M	0.5	46,174 shs	50,395 shs
MCRB Seres Therapeutics	$2.42 -4.3%	$4.24	$2.38 ▼ $29.98	$25.41M	0.31	80,780 shs	41,920 shs
NTN NTN Buzztime	$2.21	$3.89	$0.94 ▼ $7.76	$6.58M	0.72	1.63 million shs	8,312 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-7.05%	-18.23%	-27.18%	-58.41%	-81.48%
EVAX Evaxion A/S	+1.45%	-11.39%	-8.79%	-10.26%	-64.29%
MCRB Seres Therapeutics	-4.35%	-11.03%	-48.84%	-53.28%	-87.72%
NTN NTN Buzztime	0.00%	-1.12%	-46.94%	-67.16%	+70.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.26 -7.1%	$0.39	$0.25 ▼ $3.62	$25.27M	1.71	1.01 million shs	955,139 shs
EVAX Evaxion A/S	$2.80 +1.4%	$3.15	$2.72 ▼ $12.15	$24.90M	0.5	46,174 shs	50,395 shs
MCRB Seres Therapeutics	$2.42 -4.3%	$4.24	$2.38 ▼ $29.98	$25.41M	0.31	80,780 shs	41,920 shs
NTN NTN Buzztime	$2.21	$3.89	$0.94 ▼ $7.76	$6.58M	0.72	1.63 million shs	8,312 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-7.05%	-18.23%	-27.18%	-58.41%	-81.48%
EVAX Evaxion A/S	+1.45%	-11.39%	-8.79%	-10.26%	-64.29%
MCRB Seres Therapeutics	-4.35%	-11.03%	-48.84%	-53.28%	-87.72%
NTN NTN Buzztime	0.00%	-1.12%	-46.94%	-67.16%	+70.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	2.50	Moderate Buy	$6.17	2,312.62% Upside
EVAX Evaxion A/S	2.67	Moderate Buy	$11.00	292.86% Upside
MCRB Seres Therapeutics	2.25	Hold	$17.00	602.48% Upside
NTN NTN Buzztime	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NTN, CNTX, EVAX, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/12/2026	CNTX Context Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/6/2026	EVAX Evaxion A/S	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/18/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	CNTX Context Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
8/6/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	CNTX Context Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
7/17/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
EVAX Evaxion A/S	$7.53M	3.35	N/A	N/A	$2.04 per share	1.37
MCRB Seres Therapeutics	$790K	30.79	$1.04 per share	2.33	$4.89 per share	0.49
NTN NTN Buzztime	$19.81M	0.33	$0.50 per share	4.38	$1.76 per share	1.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
EVAX Evaxion A/S	-$7.71M	-$1.21	N/A	N/A	N/A	N/A	-61.43%	-34.23%	11/5/2026 (Estimated)
MCRB Seres Therapeutics	$5.70M	-$2.43	N/A	N/A	N/A	-1,192.94%	-114.82%	-34.15%	11/4/2026 (Estimated)
NTN NTN Buzztime	-$2.05M	N/A	N/A	N/A	N/A	-61.42%	-162.54%	-49.94%	N/A

Latest NTN, CNTX, EVAX, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	CNTX Context Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	MCRB Seres Therapeutics	-$1.0050	N/A	N/A	N/A	$6.35 million	N/A
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.18	$0.47	+$2.65	$0.47	$0.18 million	$0.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NTN NTN Buzztime	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	5.81	5.81
EVAX Evaxion A/S	0.69	5.06	5.06
MCRB Seres Therapeutics	N/A	2.11	2.11
NTN NTN Buzztime	3.30	0.95	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
EVAX Evaxion A/S	11.04%
MCRB Seres Therapeutics	59.34%
NTN NTN Buzztime	6.31%

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	4.80%
EVAX Evaxion A/S	41.64%
MCRB Seres Therapeutics	5.20%
NTN NTN Buzztime	24.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	15	91.88 million	87.47 million	Not Optionable
EVAX Evaxion A/S	46	9.02 million	5.27 million	No Data
MCRB Seres Therapeutics	66	10.05 million	9.52 million	Optionable
NTN NTN Buzztime	19	2.98 million	N/A	Not Optionable

NTN, CNTX, EVAX, and MCRB Headlines

Recent News About These Companies

NTN Buzztime Launches Buzztime Entertainment App in Open Beta; Players Can Use Their Smartphones to Play and Compete in Trivia

July 13, 2026 | nasdaq.com

Eterna Therapeutics sets annual meeting date, opens nominations

February 13, 2025 | msn.com

The Petri Dish: Boston biotech scores FDA approval, antiviral maker stops 3 studies

December 28, 2023 | bizjournals.com

Exclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50M

May 2, 2023 | bizjournals.com

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

April 15, 2022 | ca.finance.yahoo.com

A list of mental health startups in the Pacific Northwest, as pandemic fuels growth for sector

March 23, 2022 | geekwire.comG

My Buzzcard Login

January 13, 2022 | c21media.netC

Top 10 Penny Stocks of 2017

October 26, 2021 | finance.yahoo.com

Everyone from pharma giants to startup biotechs wants in on the hottest way to develop drugs

October 6, 2021 | msn.com

Democrats push to retool health care programs for millions

September 20, 2021 | sandiegouniontribune.comS

Sporcle Events: A New Beginning

August 31, 2021 | sporcle.comS

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTN, CNTX, EVAX, and MCRB Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.26 -0.02 (-7.05%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$0.26 +0.00 (+1.33%)

As of 07:28 AM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Evaxion A/S NASDAQ:EVAX

$2.80 +0.04 (+1.45%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$2.80 +0.01 (+0.18%)

As of 04:27 AM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Seres Therapeutics NASDAQ:MCRB

$2.42 -0.11 (-4.35%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$2.47 +0.05 (+2.11%)

As of 07:01 AM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

NTN Buzztime NYSEAMERICAN:NTN

$2.21 0.00 (0.00%)

As of 10/13/2026

NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTN, CNTX, EVAX, and MCRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTN, CNTX, EVAX, and MCRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTN, CNTX, EVAX, and MCRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTN, CNTX, EVAX, and MCRB Company Descriptions

Context Therapeutics NASDAQ:CNTX

Evaxion A/S NASDAQ:EVAX

Seres Therapeutics NASDAQ:MCRB

NTN Buzztime NYSEAMERICAN:NTN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTN, CNTX, EVAX, and MCRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTN, CNTX, EVAX, and MCRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTN, CNTX, EVAX, and MCRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTN, CNTX, EVAX, and MCRB Company Descriptions

Context Therapeutics NASDAQ:CNTX

Evaxion A/S NASDAQ:EVAX

Seres Therapeutics NASDAQ:MCRB

NTN Buzztime NYSEAMERICAN:NTN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools